Clinical Trials Browser

Phase 2/3 × INDUSTRY × spartalizumab × Clear all

NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Phase 2/3 Terminated

Uterine Cervical Neoplasms